This editorial synthesizes recent research in Acta Cardiologica covering arrhythmia management, AI-assisted ECG diagnostics, cardiometabolic and RNA biomarkers, and infiltrative cardiomyopathies, emphasizing that technological innovation must complement physician expertise.
Cardiovascular medicine continues to evolve rapidly through advances in molecular biology, biomarkers, digital technologies, and interventional strategies. Recent contributions highlight progress in arrhythmia management, artificial intelligence-assisted diagnostics, metabolic and inflammatory risk stratification, and the understanding of rare cardiomyopathies. These developments illustrate the transition towards more precise and individualised cardiovascular care while raising new clinical and ethical challenges. Integrating technological innovation with clinical expertise remains essential to ensure that advances translate into improved patient outcomes.
No takes yet. Share an insight, caveat, or question.
Lancellotti et al. (2026) conducted an editorial in Cardiovascular diseases (including atrial fibrillation, coronary artery disease, heterozygous familial hypercholesterolemia, Fabry disease, and transthyretin amyloid cardiomyopathy).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: